Former FDA commissioner joins J&J board
This article was originally published in Scrip
Johnson and Johnson has appointed Dr Mark B McClellan to its board of directors – effective 15 October 2013. He will serve on the regulatory, compliance and government affairs committee, and the science, technology and sustainability committee. Prior to joining the New Brunswick, New Jersey-headquartered firm, Dr McClellan was commissioner of the US FDA from 2002-2004 and administrator the Centers for Medicare and Medicaid services, a department of US Health and Human Services, from 2004-2006. Currently, Dr McClellan is senior fellow in economic studies, and director of the initiative on value and innovation in healthcare at Brookings Institution.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.